| Henrik Zetterberg | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Gothenburg, UCL |
| Country | Sweden, UK |
| H-index | 180 |
| ORCID | 0000-0001-8765-3408 |
| Research Focus | Alzheimer's Disease, Parkinson's Disease, Biomarkers |
| Mechanisms | Tau Pathology, Synaptic Dysfunction, Fluid Biomarkers |
Henrik Zetterberg is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Henrik Zetterberg is a leading neuroscientist specializing in biomarker research for neurodegenerative diseases. He holds professorships at both the University of Gothenburg in Sweden and University College London (UCL), making him one of the most internationally connected researchers in the field.[1]
Dr. Zetterberg's work has been instrumental in developing fluid biomarkers ( cerebrospinal fluid and blood tests) for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. His research group has identified key biomarkers that now form the foundation of modern neurodegenerative disease diagnosis and clinical trials.[2]
Dr. Zetterberg has made transformative contributions to neurodegenerative disease research:
He has led the development of CSF and blood biomarkers for tau, amyloid-beta, and neurofilament light chain (NfL), which are now used worldwide for Alzheimer's disease diagnosis and clinical trial enrollment.[3]
His research has advanced understanding of tau pathology in Alzheimer's disease and chronic traumatic encephalopathy, identifying mechanisms of tau propagation and aggregation.[4]
Dr. Zetterberg pioneered the use of neurofilament light chain as a marker of neuronal damage across multiple neurodegenerative diseases.[5]
He has served as a biomarker expert for numerous Alzheimer's disease clinical trials, helping to define patient selection criteria and outcome measures.[6]
Recent publications involving Henrik Zetterberg extend plasma/CSF biomarker interpretation into vascular risk, structural imaging, and perioperative neuroinflammation contexts.
The study of Henrik Zetterberg has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and a leading authority on biomarkers for Alzheimer's disease and other neurodegenerative conditions. His research has been instrumental in establishing cerebrospinal fluid and blood-based biomarkers for accurate diagnosis and disease monitoring.
Dr. Zetterberg's research has transformed neurodegenerative disease diagnostics by developing highly sensitive biomarker assays that can detect disease years before symptoms appear. His work on neurofilament light chain (NfL) has provided a universal marker for neuronal injury across multiple diseases.
The biomarker tests his team has developed are now used worldwide for Alzheimer's disease diagnosis, clinical trial enrichment, and treatment response monitoring.
Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and a leading authority on biomarkers for Alzheimer's disease and other neurodegenerative conditions. His research has been instrumental in establishing cerebrospinal fluid and blood-based biomarkers for accurate diagnosis and disease monitoring.
Dr. Zetterberg's research has transformed neurodegenerative disease diagnostics by developing highly sensitive biomarker assays that can detect disease years before symptoms appear. His work on neurofilament light chain (NfL) has provided a universal marker for neuronal injury across multiple diseases.
The biomarker tests his team has developed are now used worldwide for Alzheimer's disease diagnosis, clinical trial enrichment, and treatment response monitoring.
Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and a leading authority on biomarkers for Alzheimer's disease and other neurodegenerative conditions. His research has been instrumental in establishing cerebrospinal fluid and blood-based biomarkers for accurate diagnosis and disease monitoring.
Dr. Zetterberg's research has transformed neurodegenerative disease diagnostics by developing highly sensitive biomarker assays that can detect disease years before symptoms appear. His work on neurofilament light chain (NfL) has provided a universal marker for neuronal injury across multiple diseases.
The biomarker tests his team has developed are now used worldwide for Alzheimer's disease diagnosis, clinical trial enrichment, and treatment response monitoring.
Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and a leading authority on biomarkers for Alzheimer's disease and other neurodegenerative conditions. His research has been instrumental in establishing cerebrospinal fluid and blood-based biomarkers for accurate diagnosis and disease monitoring.
Dr. Zetterberg's research has transformed neurodegenerative disease diagnostics by developing highly sensitive biomarker assays that can detect disease years before symptoms appear. His work on neurofilament light chain (NfL) has provided a universal marker for neuronal injury across multiple diseases.
The biomarker tests his team has developed are now used worldwide for Alzheimer's disease diagnosis, clinical trial enrichment, and treatment response monitoring.